A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00982163
Recruitment Status : Completed
First Posted : September 23, 2009
Last Update Posted : September 23, 2009
Information provided by:
ORA, Inc.

Brief Summary:
The study was designed to evaluate the pattern of seasonal allergic signs and symptoms consistent with ongoing ocular allergic inflammation during ragweed season. It was hypothesized that a pattern of ongoing ocular allergic inflammation existed in certain subjects.

Condition or disease
Allergic Conjunctivitis

Detailed Description:
Subjects who had a positive skin test to ragweed within 24 months of Visit 1 were instructed to complete a diary, which assessed their allergic signs and symptoms 3 times a day for 4 weeks. During the in-office visits, subjects were asked to completed a quality of life questionnaire, as well as a retrospective and/or prospective eye allergy questionnaire.

Study Type : Observational
Actual Enrollment : 34 participants
Observational Model: Cohort
Time Perspective: Prospective
Study Start Date : August 2008
Actual Primary Completion Date : September 2008
Actual Study Completion Date : September 2009

Primary Outcome Measures :
  1. Diary Data [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
A community sample of subjects with allergic conjunctivitis and at least 18 years of age were enrolled into the study.

Inclusion Criteria:

  • Subjects must:

    1. be willing and able to read, sign, and date the informed consent and HIPAA documents prior to initiation of Visit 1 procedures or exams;
    2. be at least 18 years of age;
    3. be willing to avoid disallowed medication, such as anti-allergy therapies
    4. have a positive history of ocular allergies and a positive skin test reaction to ragweed within the past 24 months;
    5. have a calculated logMAR visual acuity score using the ETDRS Chart of 0.60 or better in each eye at Visit 1;

Exclusion Criteria:

  • Subjects may not:

    1. have preauricular lymphadenopathy or any ocular condition that could affect study parameters (particularly, clinically significant blepharitis, follicular conjunctivitis and iritis);
    2. have had any ocular infection within the last 30 days;
    3. have a positive diagnosis of moderate to severe dry eye syndrome (i.e., requiring daily use of artificial tears);
    4. wear contact lenses to each office visit; Note: Subjects will be allowed to use cold compresses.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00982163

United States, Massachusetts
ORA, Inc.
North Andover, Massachusetts, United States, 01845
Sponsors and Collaborators
ORA, Inc.
Principal Investigator: H. Jerome Crampton, M.D. ORA, Inc.

Responsible Party: Paul Gomes, Ophthalmic Research Associates Identifier: NCT00982163     History of Changes
Other Study ID Numbers: 08-003-26
First Posted: September 23, 2009    Key Record Dates
Last Update Posted: September 23, 2009
Last Verified: September 2009

Additional relevant MeSH terms:
Conjunctivitis, Allergic
Conjunctival Diseases
Eye Diseases
Hypersensitivity, Immediate
Immune System Diseases